Artelo Biosciences (ARTL) Stock: Buy, Sell, or Hold?
ARTL - Artelo Biosciences, Inc. Common Stock
$2.98
-0.13 (-4.18%)
▼
5d:
-13.87%
30d:
-38.81%
90d:
+159.13%
HOLD
LOW Confidence
Analysis Updated: Oct 13, 2026 12:00 AM ET
Earnings: Nov 11, 2026
27d
Get Alerted When ARTL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ARTL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ARTL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ARTL is currently trading at $2.98, which is considered oversold relative to its 30-day fair value range of $3.30 to $5.42.
Technical Outlook: Technically, ARTL is in a strong uptrend. The price is currently testing key support at $2.92. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: ARTL scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $18.00 (+504.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ARTL is in a strong uptrend. The price is currently testing key support at $2.92. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: ARTL scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $18.00 (+504.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.30 -
$5.42
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.2%)
- BULLISH: Trading 504.0% below Wall St target ($18.00)
- CAUTION: Bottoming setup, but lagging the sector by 50% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-13.9%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$3.30 -
$5.42
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.92
Resistance Level
$4.30
Current Trend
Strong Uptrend
Technical data as of
Oct 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.56
Wall Street Target
$18.00
(+504.0%)
Share & Embed Analysis
Last updated: October 14, 2026 9:16 AM ET
Data refreshes hourly during market hours. Next update: 10:16 AM
Data refreshes hourly during market hours. Next update: 10:16 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARTL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 65 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1180 | 45 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 53 HOLD |
|
ORKA
Oruka Therapeutics, Inc. |
STRONG BUY
13 analysts |
$155 | 74 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 60 HOLD |
